NKTR · Insider Trading
Nektar Therapeutics
Every open-market purchase and sale reported by NKTR officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-25 | Roy A Whitfield | Director | A | +2,000 | — |
| 2026-09-25 | Diana Brainard | Director | A | +2,000 | — |
| 2026-09-25 | R Scott Greer | Director | A | +2,000 | — |
| 2026-09-25 | Jeffrey Robert Ajer | Director | A | +2,000 | — |
| 2026-09-25 | Robert Chess | Director | A | +2,000 | — |
| 2026-08-20 | Jonathan Zalevsky | Chief R&D Officer | Sell | −186 | −$13.39K |
| 2026-08-20 | Howard W Robin | President & CEO | Sell | −418 | −$30.09K |
| 2026-07-24 | Jonathan Zalevsky | Chief R&D Officer | A | +16,500 deriv. | — |
| 2026-07-24 | Howard W Robin | President & CEO | A | +57,200 deriv. | — |
| 2026-07-02 | Jonathan Zalevsky | Chief R&D Officer | Sell | −5,681 | −$397.67K |
| 2026-06-18 | Howard W Robin | President & CEO | Sell | −20,000 | −$1.22M |
| 2026-06-17 | Jonathan Zalevsky | Chief R&D Officer | Sell | −5,538 | −$336.21K |
| 2026-05-21 | Jonathan Zalevsky | Chief R&D Officer | Sell | −199 | −$13.04K |
| 2026-05-21 | Howard W Robin | President & CEO | Sell | −444 | −$29.09K |
| 2026-02-20 | Howard W Robin | President & CEO | Sell | −423 | −$30.88K |
| 2026-02-20 | Jonathan Zalevsky | Chief R&D Officer | Sell | −180 | −$13.14K |
| 2026-01-22 | Jonathan Zalevsky | Chief R&D Officer | Sell | −3,867 | −$137.94K |
| 2025-12-23 | Jonathan Zalevsky | Chief R&D Officer | A | +6,250 | — |
| 2025-12-23 | Howard W Robin | President & CEO | A | +21,667 | — |
| 2025-11-25 | Mark Andrew Wilson | Chief Legal Officer | MIXED | +1,273 | −$34.20K |
| 2025-11-25 | Jonathan Zalevsky | Chief R&D Officer | MIXED | +1,509 | −$62.80K |
| 2025-11-25 | Howard W Robin | President & CEO | MIXED | +4,903 | −$119.80K |
| 2025-10-01 | Roy A Whitfield | Director | A | +8,000 deriv. | — |
| 2025-10-01 | Robert Chess | Director | A | +8,000 deriv. | — |
| 2025-10-01 | Diana Brainard | Director | A | +8,000 deriv. | — |
| 2025-10-01 | Jeffrey Robert Ajer | Director | A | +8,000 deriv. | — |
| 2025-10-01 | R Scott Greer | Director | A | +8,000 deriv. | — |
| 2025-09-11 | Howard W Robin | President & CEO | Sell | −6,666 | −$311.21K |
| 2025-09-08 | Jonathan Zalevsky | Chief R&D Officer | Sell | −1,721 | −$57.69K |
| 2025-09-08 | Howard W Robin | President & CEO | Sell | −11,832 | −$430.96K |
| 2025-09-04 | Jonathan Zalevsky | Chief R&D Officer | Sell | −485 | −$14.60K |
| 2025-09-04 | Howard W Robin | President & CEO | Sell | −1,500 | −$45.24K |
| 2025-08-21 | Mark Andrew Wilson | Chief Legal Officer | Sell | −676 | −$17.97K |
| 2025-08-21 | Jonathan Zalevsky | Chief R&D Officer | Sell | −725 | −$19.28K |
| 2025-08-21 | Howard W Robin | President & CEO | Sell | −1,573 | −$41.83K |
| 2025-05-21 | Mark Andrew Wilson | Chief Legal Officer | Sell | −9,996 | −$6.70K |
| 2025-05-21 | Howard W Robin | President & CEO | Sell | −23,208 | −$15.55K |
| 2025-05-21 | Jonathan Zalevsky | Chief R&D Officer | Sell | −10,712 | −$7.18K |
| 2025-02-21 | Mark Andrew Wilson | Chief Legal Officer | Sell | −11,040 | −$11.15K |
| 2025-02-21 | Howard W Robin | President & CEO | Sell | −23,774 | −$24.01K |
| 2025-02-21 | Jonathan Zalevsky | Chief R&D Officer | Sell | −10,300 | −$10.40K |
| 2024-12-26 | Mark Andrew Wilson | Chief Legal Officer | Sell | −49,962 | −$44.80K |
| 2024-12-20 | Jonathan Zalevsky | Chief R&D Officer | Sell | −51,115 | −$48.05K |
| 2024-12-19 | Howard W Robin | President & CEO | Sell | −132,030 | −$131.65K |
| 2024-12-17 | Howard W Robin | President & CEO | A | +410,625 | — |
| 2024-12-17 | Jonathan Zalevsky | Chief R&D Officer | A | +135,000 | — |
| 2024-12-17 | Mark Andrew Wilson | Chief Legal Officer | A | +165,938 | — |
| 2024-11-20 | Jonathan Zalevsky | Chief R&D Officer | Sell | −7,785 | −$7.86K |
| 2024-11-20 | Mark Andrew Wilson | Chief Legal Officer | Sell | −6,407 | −$6.47K |
| 2024-11-20 | Howard W Robin | President & CEO | Sell | −16,278 | −$16.44K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Howard W Robin | President & CEO | 54,655 | $2.11M |
| R Scott Greer | Director | 22,239 | $859.54K |
| Mark Andrew Wilson | Chief Legal Officer | 21,585 | $834.26K |
| Robert Chess | Director | 19,159 | $740.50K |
| Roy A Whitfield | Director | 17,751 | $686.08K |
| Jonathan Zalevsky | Chief R&D Officer | 9,570 | $369.88K |
| Jeffrey Robert Ajer | Director | 4,277 | $165.31K |
| Diana Brainard | Director | 3,904 | $150.89K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the NKTR quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.